HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): A. Marc Gillinov Ramon Diaz Eugene H. Blackstone Gösta B. Pettersson Joseph F. Sabik Bruce W. Lytle Delos M. Cosgrove, III Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gillinov, A. M. Articles by Cosgrove, D. M. Search for Related Content PubMed PubMed Citation Articles by Gillinov, A. M. Articles by Cosgrove, D. M., III Related Collections Valve disease

Ann Thorac Surg 2001;71:1874-1879
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Double valve endocarditis

^a Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Accepted for publication February 22, 2001.

Address reprint requests to Dr Gillinov, Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, F25, 9500 Euclid Ave, Cleveland, OH 44195
e-mail: gillinom{at}ccf.org

	Abstract

Top Abstract Introduction Patients and methods Results Comment References

 
Background. There are little data concerning surgical outcomes in patients with native valve endocarditis affecting both the aortic and mitral valves.

Methods. From 1977 to 1998, 54 patients had simultaneous aortic and mitral valve grafting for native valve endocarditis. In 78%, mitral valve involvement was limited to the anterior leaflet, suggesting a jet lesion from the aortic valve. Surgical strategies included 31 valve repairs and valve replacement with mechanical (34), bioprosthetic (34), or allograft (9) prostheses. Three hundred twenty-five patient-years of follow-up were available for analysis (mean 6.0 ± 4.8 years).

Results. There were no hospital deaths. Ten-year survival was 73%. Ten-year freedom from recurrent endocarditis was 84%, with risk peaking at 3 months, followed by a constant risk of 1.3%/yr. Choice of valvar procedure did not influence mortality or reinfection risk.

Conclusions. The most common pattern of double valve infection was a jet lesion on the anterior mitral leaflet. Surgical treatment has late survival and freedom from reinfection similar to those of patients with single heart valve infection.

	Introduction

Top Abstract Introduction Patients and methods Results Comment References

 
Surgical treatment of native valve endocarditis (NVE) involving either the aortic or mitral valve is well described, with excellent results reported with both valve repair and valve replacement [1–5]. There is little information, however, concerning patients with NVE that affects simultaneously both the aortic and mitral valves. The purpose of this study was to determine the pathology, surgical strategies, and outcomes of patients with double valve endocarditis.

	Patients and methods

Top Abstract Introduction Patients and methods Results Comment References

 
Patients
From 1977 to 1998, 54 patients with NVE affecting both the aortic and mitral valves underwent valvar heart procedures. Mean age was 50 ± 15 years (range, 17 to 77 years); 76% were men. At the time of operation, 7% were in New York Heart Association functional class I, 65% in class II, 13% in class III, and 15% in class IV. Left ventricular function was normal in 74% of patients.

The diagnosis of aortic and mitral valve endocarditis was made using standard criteria [6, 7]. In patients with preoperative echocardiograms, the Duke criteria for diagnosis were applied [8]. Endocarditis was considered to be active when these conditions were met and operation was undertaken within 2 months of diagnosis or in the presence of signs of active infection by macroscopic or microscopic findings at the time of operation or by culture from operative specimens [6]. Characteristics of the patients and the infection are detailed in Tables 1 and 2. Endocarditis was active in 50% and remote/healed in 50%. Responsible organisms were predominantly Streptococcal species, Staphylococcal species, and Hemophilus species. Probable sources of infection were identified in 22 patients, with 11 infections attributed to dental sources. Aortic involvement included multiple cusps in 17 patients. Seventy-eight percent of patients had 3 or 4+ aortic regurgitation, and 70% had 3 or 4+ mitral regurgitation. In 14 patients with anterior mitral leaflet involvement, a "windsock" lesion was observed. No patient had contiguous spread from one valve to another or involvement of the fibrous trigones. Four patients had extension to the conduction system, and 2 patients had intracardiac fistulas.

Table 3 lists the valvar procedures performed. In 41% of patients, mitral valve repair was performed, including 33% of patients with active endocarditis and 48% of patients with remote endocarditis. Mitral valve repair has become increasingly the norm in more recent years (Fig 1A). A variety of mitral repair techniques were used, with pericardial patch repair of the anterior mitral leaflet being the most commonly applied technique (Table 4). Only one-half of patients having mitral valve repair had an annuloplasty. Aortic allografts have recently become the prosthesis of choice for management of the aortic valve infection (Fig 1B). Additional cardiac procedures included coronary artery bypass grafting (6 patients), tricuspid valve repair (1 patient), arch aneurysm repair (1 patient), and myectomy (1 patient).

View larger version (15K): [in this window] [in a new window]   Fig 1. Trends in surgical management of the mitral and aortic valves in double valve endocarditis. The patients have been lumped with 3-year intervals, and the percentages refer to the 3-year totals. (A) Use of mitral valve repair. The logistic p for trend over calendar time was 0.007. (B) Use of allograft as aortic prosthesis. The logistic p for trend with calendar time was 0.005.

Follow-up
Follow-up was obtained by direct contact with the patient, referring physician, or both. One patient was lost to follow-up after hospital discharge. There were 325 patient-years of follow-up available for analysis, and mean follow-up interval was 6.0 ± 4.6 years. In 44% of patients, follow-up exceeded 5 years, and in 16% it exceeded 10 years. Although follow-up extended as long as 18 years, time-related events will be presented only to 12 years, at which time only 4 patients were being traced.

Methods of analysis
Events after operation (death, recurrent endocarditis, and reoperation) were analyzed in a time-related manner. Nonparametric estimates were obtained by the method of Kaplan and Meier, and are presented with asymmetric confidence limits (CL) equivalent to one standard error (68%) [9]. A parametric method was used to resolve the number of phases of instantaneous risk of events (hazard functions) and to estimate their shaping values [10]. Both the parametric and hazard function estimates are presented with confidence limits equivalent to one standard error (68%) [10].

Multivariable analyses were performed in the hazard function domain. We recognize that likely at most one factor could be resolved per outcome event. For these analyses, we examined the following variables: demography (age, sex); clinical status at operation (New York Heart Association functional class, surgical priority—elective, urgent, emergent); features of the endocarditis (active versus inactive, staphylococcal organism versus others, documented dental origin); valve pathology (presence of vegetation, abscesses, perforations, and identification of the cusp or leaflet involved in both aortic and mitral valve locations); operative details (repair versus replacement, and if replacement, prosthesis type separately for aortic and mitral locations); experience (date of operation). The p value criterion for retention of variables in the final models was 0.1.

	Results

Top Abstract Introduction Patients and methods Results Comment References

 
Hospital morbidity and mortality
There was no hospital or 30-day mortality (0%; CL 0%–3.5%). In-hospital morbidity included stroke in 5 patients (9%; CL 5%–15%), reoperation for bleeding in 8 patients (15%; CL 10%–22%), renal failure in 1 patient (2%; CL 0.2%–6%), and respiratory failure in 4 patients (7%; CL 4%–13%). Of the 8 patients who required reoperation for bleeding, 7 had active endocarditis and 1 underwent urgent or emergent operation.

Survival
There were 9 late deaths, and 10-year actuarial survival was 73% (Fig 2). Eight deaths were of cardiac origin, and 1 patient died of pneumonia. Two patients that died had recurrent endocarditis. One had infection of aortic and mitral bioprostheses and died at an outside hospital without operation. The other died after reoperation for recurrent endocarditis. Multivariable analysis demonstrated that increasing patient age (p = 0.004) and earlier date of operation (p = 0.02) decreased late survival. Pathologic findings and choice of valvar procedure could not be demonstrated to influence patient survival.

View larger version (15K): [in this window] [in a new window]   Fig 2. Survival after operation for double valve endocarditis. Each circle represents a death, positioned on the vertical axis according to the Kaplan-Meier estimation. The solid curve is the parametric estimate. Vertical bars and confidence bands are 68%, equivalent to one standard error. The number of patients traced across time is shown in parentheses.

View larger version (17K): [in this window] [in a new window]   Fig 3. Freedom from recurrent endocarditis. The depiction is formatted as in Figure 2. (A) Freedom. (B) Hazard function with expanded horizontal axis.

Reoperation
Nine patients underwent cardiac reoperation, and 10-year freedom from reoperation was 73% (Fig 4). Reasons for reoperation included endocarditis (4 patients), bioprosthetic valve degeneration (4 patients), and heart transplant for cardiomyopathy (1 patient). Only 1 of 22 patients having mitral valve repair required late reoperation (p = 0.02 versus bioprosthetic mitral replacement by log-rank test).

View larger version (18K): [in this window] [in a new window]   Fig 4. Freedom from reoperation. The depiction is formatted as in Figure 2. (A) Freedom. (B) Hazard function.

	Comment

Top Abstract Introduction Patients and methods Results Comment References

Although antibiotic therapy is often effective at treating NVE, operation is necessary in 20% to 40% of patients [6, 11–13]. The indications for surgical therapy are well established, with congestive heart failure being the most common indication for operation [6, 14]. In recent years, we have taken an increasingly aggressive approach to early surgical intervention in patients with NVE and important valvular dysfunction, thromboemboli, or persistent sepsis. Certain groups of patients, including those with hemodynamic compromise and severe aortic insufficiency, derive particular benefit from early surgical intervention [6, 13, 15]. In such patients, the duration of preoperative antibiotic therapy does not influence the timing of surgical intervention.

Although the role of operation in patients with NVE is clear, the choice of valvar procedure remains controversial. Occasionally infected aortic valves can be repaired. Aranki and coworkers [16] reported excellent results using standard prostheses to replace infected aortic valves. However, for aortic valve endocarditis, particularly when accompanied by aortic root involvement, allograft aortic valve replacement has distinct advantages. Demonstrated benefits to the allograft in this setting include a low and constant risk of recurrent endocarditis and decreased operative mortality [17–19]. In addition, technical factors favor the allograft in the presence of aortic root abscess or destruction. There has also been enthusiasm for application of the Ross procedure in patients with aortic valve endocarditis [20, 21]. This option has the advantage of placing living tissue in the aortic position, and, to date, this strategy has been associated with a low risk of reinfection [20, 21].

Surgical treatment options for NVE affecting the mitral valve include valve replacement and valve repair. Although there is some experience with the mitral valve allograft for treatment of mitral valve endocarditis, there are too little data available to support this strategy [22]. In contrast, several reports confirm the efficacy of mitral valve repair in patients with both active and healed NVE [3–5]. In this setting, mitral valve repair is associated with low operative mortality, low risk of reinfection, and low incidence of reoperation. Therefore, when feasible, mitral valve repair is the procedure of choice for surgical treatment of NVE affecting the mitral valve.

Operative mortality in patients with NVE ranges from 0% to 10% [1–5, 11–16]. Documented risk factors for increased operative mortality include nonstreptococcal infection, increasing New York Heart Association functional class, renal failure, increased age, cardiogenic shock, failure to use an allograft for aortic valve endocarditis, and mitral valve replacement instead of mitral valve repair for mitral valve endocarditis [2, 4, 11, 19, 22]. Late survival in these patients is good, with 5-year survival of approximately 80% and 10-year survival of approximately 60% [1, 2, 13, 15].

Persistent or recurrent infection is the most important morbid event after operation for NVE. Ten-year freedom from recurrent endocarditis after operation for NVE is approximately 80% [2, 16, 17, 19]. Active infection and staphylococcal infection increase the risk of recurrent endocarditis, whereas use of an allograft valve in the aortic position and mitral valve repair decrease the risk of reinfection [3–5, 18]. Although choice of valvar procedure has a modest impact on results, excision of all infected material is the cornerstone of treatment in these patients [6].

Until now, there have been little data describing pathology, surgical strategies, and results in patients with endocarditis affecting both the native aortic and mitral valves. Approximately 10% of patients with endocarditis have simultaneous aortic and mitral valve infection [1, 3, 9, 12, 13, 15, 23, 24]. Aortic valve endocarditis is generally the primary event. The most common pathologic finding is aortic valve endocarditis with an associated lesion on the anterior leaflet of the mitral valve [6, 25, 26]. The lesion on the anterior mitral leaflet may be a vegetation, aneurysm, or frank perforation. The pathogenesis of the mitral valve lesion is thought to involve a jet of aortic regurgitation that produces an infected lesion on the anterior mitral leaflet. Other less common mechanisms of anterior leaflet mitral valve involvement in patients with aortic valve endocarditis include repeated impingement of a prolapsing aortic vegetation on the anterior mitral leaflet and direct extension of infection along the mitral–aortic intervalvular fibrosa [26]. Although direct extension and involvement of the fibrous skeleton of the heart has been reported in NVE, it is exceedingly rare in this setting and was not present in any of the 54 patients in this series.

The most common approach to double valve endocarditis has been replacement of both valves [24–26]. In the current series, 41% of mitral valves and 17% of aortic valves were repaired. Repair is most applicable to the mitral valve, and in recent years we have become increasingly aggressive with mitral valve repair in the setting of endocarditis. Perforations are patched with autologous pericardium. If there is active infection and the annulus is dilated, an annuloplasty is performed with autologous or bovine pericardium and polypropylene suture; otherwise, no annuloplasty is included. On the basis of data from Haydock [17], Agnihotri [18], and McGiffin [19] and their colleagues, we favor allograft aortic valve replacement for aortic valves that are not amenable to repair. This is a recent change in our practice, which accounts for the small number of allografts in this report.

Results of operation for NVE affecting the aortic and mitral valves were gratifying. There was no operative mortality, and operative morbidity was low. This may be attributable in part to the fact that 50% of patients had remote endocarditis and the majority of patients had elective operation. Ten-year survival was 73%, which is similar to that for endocarditis affecting a single native valve [2, 13, 15]. Ten-year freedom from recurrent endocarditis was 84%, which is also similar to that reported for single valve endocarditis [2, 16, 17, 19]. Small numbers of patients limited our ability to determine risk factors for late mortality and recurrent infection. Nevertheless, data from previous series of patients with single valve endocarditis support a strategy of aggressive debridement, valve repair when possible, and allograft replacement of the aortic valve when repair is not feasible.

This is a clinical study of a relatively small number of patients. This limitation may be responsible for our inability to demonstrate outcome differences between patients with active and remote endocarditis or superiority of one surgical technique over another.

In conclusion, the most common pattern of double native valve infection includes a jet lesion on the anterior mitral leaflet. A surgical strategy that uses valve repair whenever feasible is suggested. Surgical treatment of double valve endocarditis is accompanied by good early results and late survival and freedom from recurrent infection that are similar to those found in patients with infection of only one valve.

	References

Top Abstract Introduction Patients and methods Results Comment References

 

1. David T.E., Bos J., Christakis G.T., Brofman P.R., Wong D., Feindel C.M. Heart valve operations in patients with active infective endocarditis. Ann Thorac Surg 1990;49:701-705.[Abstract]
2. Larbalestier R.I., Kinchla N.M., Aranki S.F., Couper G.S., Collins J.J., Jr, Cohn L.H. Acute bacterial endocarditis: optimizing surgical results. Circulation 1992;86(Suppl 2):68-74.
3. Dreyfus G., Serraf A., Jebara V.A., et al. Valve repair in acute endocarditis. Ann Thorac Surg 1990;49:706-713.[Abstract]
4. Muehrcke D.D., Cosgrove D.M., III, Lytle B.W., et al. Is there an advantage to repairing infected mitral valves?. Ann Thorac Surg 1997;63:1718-1724.[Abstract/Free Full Text]
5. Hendren W.G., Morris A.S., Rosenkranz E.R., et al. Mitral valve repair for bacterial endocarditis. J Thorac Cardiovasc Surg 1992;103:124-129.[Abstract]
6. Pettersson G., Carbon C., Endocarditis Working Group of the International Society of Chemotherapy. Recommendations for the surgical treatment of endocarditis. Clin Microbiol Infect 1998;4:3S34-3S46.
7. Von Reyn C.F., Levy B.S., Arbeit R.D., Friedland G., Crumpacker C.S. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med 1981;94:505-518.
8. Durack D.T., Lukes A.S., Bright D.K., Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med 1994;96:200-209.[Medline]
9. Kirklin JW, Barratt-Boyes BG. Surgical concepts, research methods, and data analysis and use. In: Cardiac surgery. New York: John Wiley, 1986:177–204.
10. Blackstone E.H., Naftel D.C., Turner M.E., Jr The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assn 1986;81:615-624.
11. Croft C.H., Woodward W., Elliott A., Commerford P.J., Barnard C.N., Beck W. Analysis of surgical versus medical therapy in active complicated native valve infective endocarditis. Am J Cardiol 1983;51:1650-1655.[Medline]
12. Sandre R.M., Shafran S.D. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996;22:276-286.[Medline]
13. Vlessis A.A., Hovaguimian H., Jaggers J., Ahmad A., Starr A. Infective endocarditis: ten-year review of medical and surgical therapy. Ann Thorac Surg 1996;61:1217-1222.[Abstract/Free Full Text]
14. Alsip S.G., Blackstone E.H., Kirklin J.W., Cobbs C.G. Indications for cardiac surgery in patients with active infective endocarditis. Am J Med 1985;78(Suppl 6B):138-148.[Medline]
15. Middlemost S., Wisenbaugh T., Meyerowitz C., et al. A case for early surgery in native left-sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol 1991;18:663-667.[Abstract]
16. Aranki S.F., Santini F., Adams D.H., et al. Aortic valve endocarditis: determinants of early survival and late morbidity. Circulation 1994;90(Part 2):175-182.
17. Haydock D., Barratt-Boyes B., Macedo T., Kirklin J.W., Blackstone E. Aortic valve replacement for active infectious endocarditis in 108 patients. J Thorac Cardiovasc Surg 1992;103:130-139.[Abstract]
18. Agnihotri A.K., McGiffin D.C., Galbraith A.J., O’Brien M.F. The prevalence of infective endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg 1995;110:1708-1724.[Abstract/Free Full Text]
19. McGiffin D.C., Galbraith A.J., McLachlan G.J., et al. Aortic valve infection: risk factors for death and recurrent endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg 1992;104:511-520.[Abstract]
20. Joyce F., Tingleff J., Pettersson G. Changing indications for the Ross operation. Semin Thorac Cardiovasc Surg 1996;8:336-344.[Medline]
21. Joyce F., Tingleff J., Pettersson G. The Ross operation: results of early experience including treatment for endocarditis. Eur J Cardiothorac Surg 1995;9:384-392.[Abstract]
22. Reardon M.J., Vinnerkvist A., LeMaire S.A. Mitral valve homograft for mitral valve replacement in acute bacterial endocarditis. J Heart Valve Dis 1999;8:71-73.[Medline]
23. Jault F., Gandjbakhch I., Rama A., et al. Active native valve endocarditis: determinants of operative death and late mortality. Ann Thorac Surg 1997;63:1737-1741.[Abstract/Free Full Text]
24. Lewis B.S., Agathangelou N.E., Colsen P.R., Antunes M., Kinsley R.H. Cardiac operation during active infective endocarditis: results of aortic, mitral, and double valve replacement in 94 patients. J Thorac Cardiovasc Surg 1982;84:579-584.[Abstract]
25. Decroly P.H., Vandenbossche J.L., Englert M. Anterior mitral valve aneurysm perforation secondary to aortic valve endocarditis detected by Doppler colour flow mapping. Eur Heart J 1989;10:186-189.[Abstract/Free Full Text]
26. De Castro S., d’Amati G., Cartoni D., et al. Valvular perforation in left-sided infective endocarditis: a prospective echocardiographic evaluation and clinical outcome. Am Heart J 1997;134:656-664.[Medline]

This article has been cited by other articles:

				A. M. Sheikh, A. M. Elhenawy, M. Maganti, S. Armstrong, T. E. David, and C. M. Feindel Outcomes of double valve surgery for active infective endocarditis J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 69 - 75. [Abstract] [Full Text] [PDF]

				F. Yao, L. Han, Z.-y. Xu, L.-j. Zou, S.-d. Huang, Z.-n. Wang, F.-l. Lu, and Y.-l. Yao Surgical treatment of multivalvular endocarditis: Twenty-one-year single center experience. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1475 - 1480. [Abstract] [Full Text] [PDF]

				A. M. Sheikh, A. M. Elhenawy, M. Maganti, S. Armstrong, T. E. David, and C. M. Feindel Outcomes of surgical intervention for isolated active mitral valve endocarditis. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 110 - 116. [Abstract] [Full Text] [PDF]

				T. E. David Surgical Treatment of Aortic Valve Endocarditis Card. Surg. Adult, January 1, 2008; 3(2008): 949 - 956. [Full Text]

				S. C. Stamou, G. Petterson, and A. M. Gillinov Surgical Treatment of Mitral Valve Endocarditis Card. Surg. Adult, January 1, 2008; 3(2008): 1069 - 1078. [Full Text]

				A. M. Gillinov, E. H. Blackstone, D. M. Cosgrove III, J. White, P. Kerr, A. Marullo, P. M. McCarthy, and B. W. Lytle Mitral valve repair with aortic valve replacement is superior to double valve replacement J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1372 - 1387. [Abstract] [Full Text] [PDF]

				T. E. David Surgical Treatment of Aortic Valve Endocarditis Card. Surg. Adult, January 1, 2003; 2(2003): 857 - 866. [Full Text]

				F. Filsoufi and D. H. Adams Surgical Treatment of Mitral Valve Endocarditis Card. Surg. Adult, January 1, 2003; 2(2003): 987 - 997. [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): A. Marc Gillinov Ramon Diaz Eugene H. Blackstone Gösta B. Pettersson Joseph F. Sabik Bruce W. Lytle Delos M. Cosgrove, III Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gillinov, A. M. Articles by Cosgrove, D. M. Search for Related Content PubMed PubMed Citation Articles by Gillinov, A. M. Articles by Cosgrove, D. M., III Related Collections Valve disease